{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:31:06Z","timestamp":1793640666264,"version":"4.5.1"},"reference-count":15,"publisher":null,"issue":"4","license":[{"start":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T00:00:00Z","timestamp":1714435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/lib.ossn.ru\/jour\/about\/editorialPolicies#openAccessPolicy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kardiologiia"],"abstract":"<jats:p>\n                    <jats:italic>Aim<\/jats:italic>\n                    . To estimate the prevalence of amyloid cardiomyopathy (CM) caused by transthyretin amyloidosis (ATTR) and immunoglobulin light chain (AL) amyloidosis among patients aged\n                    <jats:underline>&gt;<\/jats:underline>\n                    65 years with interventricular septal (IVS) hypertrophy of \u226514\u2008mm.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Material and methods<\/jats:italic>\n                    . From January through August 2023, 60 patients (mean age 7.2\u00b17.3 years, 34 (56.67%) men) were enrolled. Patients meeting the inclusion criteria underwent an echocardiographic study with determining the myocardial longitudinal strain, myocardial scintigraphy with 99mTc-pyrfotech, myocardial single-photon emission computed tomography, measurement of N-terminal fragment of brain natriuretic peptide and troponin I, and the immunochemical study of serum and urine proteins with measurement of free light chains. In the presence of grades 2 and 3 radiopharmaceutical uptake according to scintigraphy, a molecular genetic study was performed for differential diagnosis of wild-type transthyretin amyloidosis (wtATTR) and hereditary\/variant (hATTR) ATTR-CM.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Results<\/jats:italic>\n                    . According to data of myocardial scintigraphy with 99mTc-pyrfotech, grade 3 uptake in the absence of monoclonal secretion was detected in 5 (8.3%) cases and grade 2 radiotracer uptake in the absence of monoclonal secretion was detected in 6 (10%) patients. Myeloma complicated by AL amyloidosis and primary AL amyloidosis were found in 5 (8.3%) patients.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Conclusion<\/jats:italic>\n                    . Among patients aged \u226565 years with IVS hypertrophy \u226514\u2008mm, amyloid CM was detected in 20% of cases (12 patients), including 5 cases (8.3%) of AL amyloidosis and 7 cases (11.7%) of ATTR amyloidosis.\n                  <\/jats:p>","DOI":"10.18087\/cardio.2024.4.n2611","type":"journal-article","created":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T05:08:46Z","timestamp":1715663326000},"page":"54-60","source":"Crossref","is-referenced-by-count":4,"title":["Primary Data on ATTR-Amyloidosis Prevalence Among Elderly Patients With Left Ventricular Hypertrophy in Russia"],"prefix":"10.68900","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3072-8951","authenticated-orcid":true,"given":"T. V.","family":"Nikiforova","sequence":"first","affiliation":[{"name":"Sechenov First Moscow State Medical University, Moscow"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7071-5752","authenticated-orcid":true,"given":"K. V.","family":"Charaya","sequence":"additional","affiliation":[{"name":"Sechenov First Moscow State Medical University, Moscow"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8209-2791","authenticated-orcid":true,"given":"D. Yu.","family":"Shchekochikhin","sequence":"additional","affiliation":[{"name":"Sechenov First Moscow State Medical University, Moscow;\r\nPirogov Municipal Clinical Hospital #1, Moscow"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6753-1525","authenticated-orcid":true,"given":"Z. M.","family":"Magomedova","sequence":"additional","affiliation":[{"name":"Sechenov First Moscow State Medical University, Moscow;\r\nPirogov Municipal Clinical Hospital #1, Moscow"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. S.","family":"Enokyan","sequence":"additional","affiliation":[{"name":"Sechenov First Moscow State Medical University, Moscow"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0923-735X","authenticated-orcid":true,"given":"A. N.","family":"Volovchenko","sequence":"additional","affiliation":[{"name":"Sechenov First Moscow State Medical University, Moscow"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3735-8313","authenticated-orcid":true,"given":"A. H.","family":"Khamzatkhanova","sequence":"additional","affiliation":[{"name":"Sechenov First Moscow State Medical University, Moscow"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. A.","family":"Starovoytova","sequence":"additional","affiliation":[{"name":"Pirogov Municipal Clinical Hospital #1, Moscow"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. A.","family":"Bogdanova","sequence":"additional","affiliation":[{"name":"Sechenov First Moscow State Medical University, Moscow;\r\nPirogov Municipal Clinical Hospital #1, Moscow"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. V.","family":"Karalkin","sequence":"additional","affiliation":[{"name":"Pirogov Municipal Clinical Hospital #1, Moscow"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. P.","family":"Pasha","sequence":"additional","affiliation":[{"name":"Pirogov Municipal Clinical Hospital #1, Moscow"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. S.","family":"Pershina","sequence":"additional","affiliation":[{"name":"Sechenov First Moscow State Medical University, Moscow;\r\nPirogov Municipal Clinical Hospital #1, Moscow"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. E.","family":"Grachev","sequence":"additional","affiliation":[{"name":"National Medical Research Center of Hematology, Moscow"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4066-2661","authenticated-orcid":true,"given":"I. V.","family":"Zhirov","sequence":"additional","affiliation":[{"name":"Chazov National Medical Research Center of Cardiology, Moscow"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0276-7374","authenticated-orcid":true,"given":"D. A.","family":"Andreev","sequence":"additional","affiliation":[{"name":"Sechenov First Moscow State Medical University, Moscow"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":null,"published-online":{"date-parts":[[2024,4,30]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Lachmann H, Hawkins P. Systemic amyloidosis. Current Opinion in Pharmacology. 2006;6(2):214\u201320. DOI: 10.1016\/j.coph.2005.10.005","DOI":"10.1016\/j.coph.2005.10.005"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Bokhari S, Casta\u00f1o A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. (99m) Tc-Pyrophosphate Scintigraphy for Differentiating Light-Chain Cardiac Amyloidosis From the Transthyretin-Related Familial and Senile Cardiac Amyloidoses. Circulation: Cardiovascular Imaging. 2013;6(2):195\u2013201. DOI: 10.1161\/CIRCIMAGING.112.000132","DOI":"10.1161\/CIRCIMAGING.112.000132"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Porcari A, Bussani R, Merlo M, Varr\u00e0 GG, Pagura L, Rozze D et al. Incidence and Characterization of Concealed Cardiac Amyloidosis Among Unselected Elderly Patients Undergoing Post-mortem Examination. Frontiers in Cardiovascular Medicine. 2021;8:749523. DOI: 10.3389\/fcvm.2021.749523","DOI":"10.3389\/fcvm.2021.749523"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Kittleson MM, Maurer MS, Ambardekar AV, Bullock-Palmer RP, Chang PP, Eisen HJ et al. Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association. Circulation. 2020;142(1):7\u201322. DOI: 10.1161\/CIR.0000000000000792","DOI":"10.1161\/CIR.0000000000000792"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. New England Journal of Medicine. 2018;379(11):1007\u201316. DOI: 10.1056\/NEJMoa1805689","DOI":"10.1056\/NEJMoa1805689"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Antonopoulos AS, Panagiotopoulos I, Kouroutzoglou A, Koutsis G, Toskas P, Lazaros G et al. Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta-analysis. European Journal of Heart Failure. 2022;24(9):1677\u201396. DOI: 10.1002\/ejhf.2589","DOI":"10.1002\/ejhf.2589"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Mitchell C, Rahko PS, Blauwet LA, Canaday B, Finstuen JA, Foster MC et al. Guidelines for Performing a Comprehensive Transthoracic Echocardiographic Examination in Adults: Recommendations from the American Society of Echocardiography. Journal of the American Society of Echocardiography. 2019;32(1):1\u201364. DOI: 10.1016\/j.echo.2018.06.004","DOI":"10.1016\/j.echo.2018.06.004"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA et al. ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2 \u2013 Evidence Base and Standardized Methods of Imaging. Circulation: Cardiovascular Imaging. 2021;14(7):e000029. DOI: 10.1161\/HCI.0000000000000029","DOI":"10.1161\/HCI.0000000000000029"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Schockling EJ, Farrell MB, Embry-Dierson M, Warren J, Jerome S. Cardiac Amyloidosis Imaging, Part 2: Quantification and Technical Considerations. Journal of Nuclear Medicine Technology. 2023;51(2):90\u20138. DOI: 10.2967\/jnmt.123.265416","DOI":"10.2967\/jnmt.123.265416"},{"key":"ref10","unstructured":"Reznik E.V., Stepanova E.A., Nguyen T.L., Sirenova I.O., Salikov A.V., Nikitin I.G. Retrospective analysis of cardiovascular involvement in patients with systemic amyloidosis. Cardiovascular Therapy and Prevention. 2021;20(1):35\u201346. DOI: 10.15829\/1728-8800-2021-2496"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Tanskanen M, Peuralinna T, Polvikoski T, Notkola I, Sulkava R, Hardy J et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Annals of Medicine. 2008;40(3):232\u20139. DOI: 10.1080\/07853890701842988","DOI":"10.1080\/07853890701842988"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez-L\u00f3pez E, Gallego-Delgado M, Guzzo-Merello G, de Haro-del Moral FJ, Cobo-Marcos M, Robles C et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. European Heart Journal. 2015;36(38):2585\u201394. DOI: 10.1093\/eurheartj\/ehv338","DOI":"10.1093\/eurheartj\/ehv338"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"AbouEzzeddine OF, Davies DR, Scott CG, Fayyaz AU, Askew JW, McKie PM et al. Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction. JAMA Cardiology. 2021;6(11):1267\u201374. DOI: 10.1001\/jamacardio.2021.3070","DOI":"10.1001\/jamacardio.2021.3070"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Lindmark K, Pilebro B, Sundstr\u00f6m T, Lindqvist P. Prevalence of wild type transtyrethin cardiac amyloidosis in a heart failure clinic. ESC Heart Failure. 2021;8(1):745\u20139. DOI: 10.1002\/ehf2.13110","DOI":"10.1002\/ehf2.13110"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Tereshchenko S.N., Zhirov I.V., Moiseeva O.M., Adasheva T.V., Ansheles A.A., Barbarash O.L. et al. Practical guidelines for the diagnosis and treatment of transthyretin amyloid cardiomyopathy (ATTR-CM or transthyretin cardiac amyloidosis). Therapeutic Archive. 2022;94(4):584\u201395. DOI: 10.26442\/00403660.2022.04.201465","DOI":"10.26442\/00403660.2022.04.201465"}],"container-title":["Kardiologiia"],"original-title":[],"link":[{"URL":"https:\/\/lib.ossn.ru\/jour\/article\/viewFile\/2611\/1547","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:16:37Z","timestamp":1793639797000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardio.elpub.ru\/jour\/article\/view\/2611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,30]]},"references-count":15,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4,30]]}},"URL":"https:\/\/doi.org\/10.18087\/cardio.2024.4.n2611","relation":{},"ISSN":["2412-5660","0022-9040"],"issn-type":[{"value":"2412-5660","type":"electronic"},{"value":"0022-9040","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,30]]}}}